Logos Global Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Logos Global Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-300,000	Closed	-$13.1M	–	77
2023 Q3	$13.1M	Buy	+300,000	New	+$10.7M	1.74%	21
2022 Q2	–	Sell	-350,000	Closed	-$28.8M	–	47
2022 Q1	$28.8M	Buy	350,000 +300,000	+600%	+$30.7M	3.73%	13
2021 Q4	$7.33M	Buy	+50,000	New	+$7.76M	0.76%	31
2021 Q1	–	Sell	-50,000	Closed	-$11M	–	76
2020 Q4	$11M	Buy	+50,000	New	+$10.8M	0.94%	24
2020 Q2	–	Sell	-46,399	Closed	-$3.57M	–	69
2020 Q1	$3.57M	Sell	46,399 -207,261	-82%	-$18.6M	1.36%	31
2019 Q4	$32.7M	Buy	+253,660	New	+$24.5M	8.06%	1

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Logos Global Management's MRTX Position: Q4 2023 in Review

Logos Global Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 300,000 shares — an estimated $13.1M sold.

Logos Global Management first reported a position in MRTX in Q4 2019 and held it in 6 quarters. The position peaked at $32.7M in Q4 2019. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Logos Global Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Logos Global Management sold 300,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $13.1M.
Logos Global Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 6 quarters.
Logos Global Management's Mirati Therapeutics, Inc. Common Stock position peaked at $32.7M in Q4 2019.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Logos Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.